Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT.

Ma KH, Liu TT, Weng SJ, Chen CF, Huang YS, Chueh SH, Liao MH, Chang KW, Sung CC, Hsu TH, Huang WS, Cheng CY.

Sci Rep. 2016 Dec 12;6:38695. doi: 10.1038/srep38695.

2.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3473-501. doi: 10.1007/s00213-016-4396-5. Epub 2016 Aug 28. Review.

3.

Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users.

Bosch OG, Wagner M, Jessen F, Kühn KU, Joe A, Seifritz E, Maier W, Biersack HJ, Quednow BB.

PLoS One. 2013 Apr 9;8(4):e61234. doi: 10.1371/journal.pone.0061234. Print 2013.

4.

Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.

Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M.

Neuropsychopharmacology. 2012 May;37(6):1465-73. doi: 10.1038/npp.2011.332. Epub 2012 Feb 22.

5.
6.

Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys.

Gould RW, Gage HD, Banks ML, Blaylock BL, Czoty PW, Nader MA.

Neuropharmacology. 2011 Jul-Aug;61(1-2):245-51. doi: 10.1016/j.neuropharm.2011.04.007. Epub 2011 Apr 17.

7.

Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Mueller M, Goodwin AK, Ator NA, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2011 Jul;338(1):310-7. doi: 10.1124/jpet.111.180612. Epub 2011 Apr 14.

8.

Neuroimaging and drug taking in primates.

Murnane KS, Howell LL.

Psychopharmacology (Berl). 2011 Jul;216(2):153-71. doi: 10.1007/s00213-011-2222-7. Epub 2011 Mar 1. Review.

9.

Nonhuman primate positron emission tomography neuroimaging in drug abuse research.

Howell LL, Murnane KS.

J Pharmacol Exp Ther. 2011 May;337(2):324-34. doi: 10.1124/jpet.108.136689. Epub 2011 Feb 11.

10.

MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain.

Perrine SA, Ghoddoussi F, Michaels MS, Hyde EM, Kuhn DM, Galloway MP.

Neurotoxicology. 2010 Dec;31(6):654-61. doi: 10.1016/j.neuro.2010.08.005. Epub 2010 Aug 26.

11.

Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I.

Brain. 2010 Jun;133(Pt 6):1779-97. doi: 10.1093/brain/awq103. Epub 2010 May 17.

12.

Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users.

McCann UD, Wilson MJ, Sgambati FP, Ricaurte GA.

J Neurosci. 2009 Nov 4;29(44):14050-6. doi: 10.1523/JNEUROSCI.4654-09.2009.

13.

Nonhuman primate neuroimaging and the neurobiology of psychostimulant addiction.

Howell LL, Murnane KS.

Ann N Y Acad Sci. 2008 Oct;1141:176-94. doi: 10.1196/annals.1441.023. Review.

14.

2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.

Parhi AK, Wang JL, Oya S, Choi SR, Kung MP, Kung HF.

J Med Chem. 2007 Dec 27;50(26):6673-84. Epub 2007 Dec 4.

15.

Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys.

Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S, Nader MA.

Neuropsychopharmacology. 2008 Jan;33(2):219-25. Epub 2007 Apr 18.

16.

Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Medina KL, Shear PK.

Drug Alcohol Depend. 2007 Mar 16;87(2-3):303-11. Epub 2006 Oct 30.

17.

Neuropsychological function in ecstasy users: a study controlling for polydrug use.

Roiser JP, Rogers RD, Sahakian BJ.

Psychopharmacology (Berl). 2007 Jan;189(4):505-16. Epub 2005 Sep 15.

18.

Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Neuropsychopharmacology. 2005 Sep;30(9):1741-50.

19.

Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA.

J Nucl Med. 2002 May;43(5):678-92. Erratum in: J Nucl Med 2002 Jun;43(6):744.

Supplemental Content

Support Center